`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MASSACHUSETTS
`
`
`
`
`
`))))))))))
`
`
`
`
`
`
`
`
`C.A. No. _________
`
`
`
`
`
`COMPLAINT
`
`PURDUE PHARMA L.P.,
`PURDUE PHARMACEUTICALS L.P.,
`and RHODES TECHNOLOGIES,
`
`
`Plaintiffs,
`
`v.
`
`
`COLLEGIUM PHARMACEUTICAL, INC.,
`
`
`Defendant.
`
`Plaintiffs Purdue Pharma L.P., Purdue Pharmaceuticals L.P., and Rhodes Technologies
`
`(collectively, “Purdue” or “Plaintiffs”), for their Complaint against Collegium Pharmaceutical,
`
`Inc. (“Collegium” or “Defendant”), aver as follows:
`
`NATURE OF THE ACTION
`
`1.
`
`This is an action for relief from patent infringement, arising under the
`
`patent laws of the United States, Title 35, United States Code for infringement of U.S. Patent No.
`
`10,407,434 (“the ’434 patent”). This action relates to Collegium’s submission of New Drug
`
`Application (“NDA”) No. 208090 (including any amendments and/or supplements thereto,
`
`“Collegium’s NDA”) to the U.S. Food & Drug Administration (“FDA”), under § 505(b)(2) of the
`
`Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(b)(2)), seeking approval to engage in the
`
`commercial manufacture, use, sale, offer for sale or importation of Xtampza® ER oxycodone
`
`extended release capsules, 9 mg, 13.5 mg, 18 mg, 27 mg, and 36 mg (“the Collegium NDA
`
`Products”) before the expiration of the ’434 patent.
`
`2.
`
`Plaintiffs seek judgment that Defendant has infringed the ’434 patent.
`
`The ’434 patent is listed in the FDA Approved Drug Products With Therapeutic Equivalence
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 2 of 15
`
`
`
`Evaluations (“Orange Book”) as covering Purdue’s OxyContin® (oxycodone hydrochloride)
`
`(“OxyContin”), an extended-release pain medication. Collegium has infringed the ’434 patent
`
`under 35 U.S.C. § 271(e)(2)(A) by filing the Collegium NDA on the Collegium NDA Products
`
`and under 35 U.S.C. §§ 271(a), (b), (c), and (g) by actual marketing of the Collegium NDA
`
`Products.
`
`3.
`
`The present action is related to currently-pending patent infringement
`
`actions Purdue previously filed against Collegium that also relate to the filing of Collegium’s NDA
`
`and Collegium’s marketing of the Collegium NDA Products. These previously-filed actions
`
`include Case No. 15-cv-13099-FDS (“the Lead Action”), in which Purdue has asserted
`
`infringement of U.S. Patent Nos. 9,073,933 (“the ’933 patent”) and 9,522,919 (“the ’919 patent”),
`
`patents that are related to the ’434 patent. The ’434, ’933, and ’919 patents share, e.g., the same
`
`claim of priority, same inventors and same specification.
`
`4.
`
`These previously-filed actions also include Case No. 17-cv-11814-FDS
`
`(the “’961 Patent Action”), in which Purdue has asserted infringement of U.S. Patent No.
`
`9,693,961 (“the ’961 patent”). The ’961 Patent Action, which has been consolidated with the Lead
`
`Action for pretrial purposes, is related to the present action in that, inter alia, they both involve the
`
`same infringing product, the Collegium NDA Products.
`
`5.
`
`Purdue and Collegium have agreed to consolidate the present action with
`
`the Lead Action for pretrial purposes, subject to the Court’s approval.
`
`THE PARTIES
`
`6.
`
`Purdue Pharma L.P. (“Purdue Pharma”) is a limited partnership
`
`organized and existing under the laws of the State of Delaware, having a place of business at One
`
`Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901-3431. Purdue Pharma is an owner
`
`
`
`- 2 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 3 of 15
`
`
`
`of the ’434 patent. Purdue Pharma is also the holder of NDA No. 022272 for the extended-release
`
`oxycodone pain-relief medication OxyContin and is involved in the sale of OxyContin in the
`
`United States.
`
`7.
`
`Purdue Pharmaceuticals L.P. (“Purdue Pharmaceuticals”) is a limited
`
`partnership organized and existing under the laws of the State of Delaware, having a place of
`
`business at 4701 Purdue Drive, Wilson, NC 27893. Purdue Pharmaceuticals is an owner of the
`
`’434 patent, and is involved in the manufacture of OxyContin.
`
`8.
`
`Rhodes Technologies (“Rhodes”) is a general partnership organized and
`
`existing under the laws of the State of Delaware, having a place of business at 498 Washington
`
`Street, Coventry, RI 02816. Rhodes is an owner of the ’434 patent, and is involved in the
`
`manufacture of the active pharmaceutical ingredient (“API”) used in OxyContin.
`
`9.
`
`Upon information and belief, Collegium is a corporation organized and
`
`existing under the laws of the Commonwealth of Virginia, having its principal place of business
`
`at 780 Dedham Street, Suite 800, Canton, MA 02021.
`
`JURISDICTION AND VENUE
`
`10.
`
`This action arises under the patent laws of the United States, including
`
`35 U.S.C. § 271.
`
`11.
`
`This Court has jurisdiction over the subject matter of this action pursuant
`
`to 28 U.S.C. §§ 1331 and 1338(a).
`
`12.
`
`This Court has personal jurisdiction over Collegium, and venue is proper
`
`in this Judicial District under 28 U.S.C. §§ 1391(b) and (c) and § 1400(b), because Collegium has
`
`its principal place of business in this Judicial District.
`
`13.
`
`Collegium is in the business of preparing pharmaceuticals that it
`
`distributes in the Commonwealth of Massachusetts and throughout the United States.
`
`
`
`- 3 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 4 of 15
`
`
`
`14.
`
`Upon information and belief, once Collegium’s NDA was approved, the
`
`Collegium NDA Products were, among other things, marketed and distributed in Massachusetts,
`
`and/or prescribed by physicians practicing and dispensed by pharmacies located within
`
`Massachusetts, all of which have a substantial effect on Massachusetts.
`
`THE ’434 PATENT
`
`15.
`
`The Orange Book identifies drug products that have been approved by
`
`the FDA under the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.). The Orange
`
`Book also provides a listing of certain patents that cover a given drug product or the use thereof.
`
`16.
`
`Purdue is the lawful owner of all right, title, and interest in the ’434
`
`patent, entitled “PROCESS FOR PREPARING OXYCODONE COMPOSITIONS,” including all
`
`right to sue and to recover for past infringement thereof, which patent is listed in the FDA’s
`
`Orange Book as covering the drug OxyContin, which is the subject of approved NDA No.
`
`022272. The ’434 patent was duly and legally issued on September 10, 2019, naming Robert
`
`Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, and Robert Kupper as the inventors. A copy of
`
`the ’434 patent is attached as Exhibit A .
`
`COLLEGIUM’S NDA
`
`17.
`
`Upon information and belief, Collegium submitted Collegium’s NDA to
`
`the FDA under § 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355(b)(2)),
`
`seeking approval to engage in the commercial manufacture, use, sale, offer for sale, or importation
`
`of the Collegium NDA Products.
`
`18.
`
`On or about April 26, 2016, the FDA issued its final approval of
`
`Collegium’s NDA based on Collegium’s filings as of that date.
`
`19.
`
`On June 20, 2016, Collegium issued a press release announcing the
`
`commercial launch of the Collegium NDA Products.
`
`
`
`- 4 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 5 of 15
`
`
`
`20.
`
`Collegium has begun commercial manufacture of the Collegium NDA
`
`Products, has begun offering for sale and selling the Collegium NDA Products, and continues to
`
`manufacture (or have manufactured), offer for sale, sell, and distribute the Collegium NDA
`
`Products, including in this district.
`
`21.
`
`After having already begun marketing the Collegium NDA Products, on
`
`or about October 4, 2016, Collegium filed a supplemental application relating to Collegium’s NDA
`
`(“Collegium’s sNDA”).
`
`22.
`
`On or about November 6, 2017, the FDA issued its final approval of
`
`Collegium’s sNDA.
`
`23.
`
`On information and belief, Collegium has marketed the Collegium NDA
`
`Products according to Collegium’s sNDA.
`
`CLAIMS FOR RELIEF:
`
`COUNT I
`(Collegium’s Filing of Its NDA Constitutes Infringement of the ’434 Patent)
`
`24.
`
`Purdue incorporates by reference and realleges paragraphs 1-23 above as
`
`
`
`though fully restated herein.
`
`25.
`
`Collegium’s submission of its NDA for a drug claimed in the ’434 patent
`
`was an act of infringement under the United States Patent Law, 35 U.S.C. § 271(e)(2)(A).
`
`26.
`
`Upon information and belief, the Collegium NDA Products use or,
`
`according to Collegium, contain oxycodone base. The oxycodone base and the process by which
`
`the oxycodone base is made is covered by one or more claims of the ’434 patent, including but not
`
`limited to at least claims 1-7, 9, 13-15, 17, and 19, which recite, inter alia, a process of purifying
`
`oxycodone free base or oxycodone HCl that contains 8α,14-dihydroxy-7,8-dihydrocodeinone; a
`
`process of purifying oxycodone free base or oxycodone HCl that contains 8α,14-dihydroxy-7,8-
`
`
`
`- 5 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 6 of 15
`
`
`
`dihydrocodeinone, wherein the ratio of 8α, 14-dihydroxy-7,8-dihydrocodeinone or HCl salt
`
`thereof to oxycodone free base or oxycodone HCl following step (i) is 0.04% or less as measured
`
`by HPLC; and purified oxycodone free base prepared according to such processes, wherein the
`
`ratio of 8α, 14-dihydroxy-7,8-dihydrocodeinone to oxycodone free base is 0.04% or less as
`
`measured by HPLC.
`
`27.
`
`For example, upon information and belief, the oxycodone base used in
`
`the Collegium NDA Products is made according to the process of independent claim 1 of the ’434
`
`patent. More specifically, the oxycodone base, which Collegium uses in its manufacture of the
`
`Collegium NDA Products, is made in a process that includes purifying oxycodone free base that
`
`contains 8α,14-dihydroxy-7,8-dihydrocodeinone. That process comprises:
`
`(i)
`
`reducing the amount of 8α,14-dihydroxy-7,8-dihydrocodeinone in the
`
`oxycodone free base;
`
`(ii)
`
`dissolving the resultant oxycodone free base from step (i) in a suitable
`
`recrystallization solvent;
`
`(iii)
`
`cooling the recrystallization solvent to precipitate purified oxycodone free
`
`base; and
`
`(iv)
`
`recovering the purified oxycodone free base.
`
`28.
`
`Based upon knowledge of Noramco Inc.’s (“Noramco”) oxycodone
`
`process and documents produced in the Lead Action, Noramco performs all the steps of at least
`
`claims 1-7, 9, 13-15 and 17 of the ’434 patent.
`
`29.
`
`Upon information and belief, the oxycodone base used in the Collegium
`
`NDA Products, and the process intermediates of the oxycodone base of Noramco’s process, meets
`
`the claim element whereby the ratio of 8α, 14-dihydroxy-7,8-dihydrocodeinone or HCl salt thereof
`
`
`
`- 6 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 7 of 15
`
`
`
`to oxycodone free base or oxycodone HCl is 0.04% or less as measured by HPLC (“8α ratio claim
`
`element”) contained in certain dependent claims.
`
`30.
`
`Further, Collegium has represented to this Court that the Collegium NDA
`
`Products contain oxycodone base. Specifically, Collegium has stated that “[t]he API, or drug
`
`substance, in XTAMPZA® ER is oxycodone base, not oxycodone myristate.” Defendant
`
`Collegium Pharmaceutical, Inc.’s Local Rule 56.1 Statement Of Material Facts As To Which
`
`There Is No Genuine Issue To Be Tried, No. 15-cv-13099, D.I. 108-2 ¶ 66. In addition, Collegium
`
`has represented to this Court that “[t]he XTAMPZA® ER microspheres contain oxycodone base,
`
`myristic acid, yellow beeswax, carnauba wax, and stearoyl polyoxyl-32 glycerides.” Id. ¶ 18.
`
`31.
`
`Upon information and belief, Collegium’s commercial manufacture, use,
`
`sale, offer for sale, and/or importation of the oxycodone base and/or the Collegium NDA Products
`
`using the claimed oxycodone base has infringed, contributed to the infringement of, and/or induced
`
`the infringement of one or more claims of the ’434 patent under 35 U.S.C. §§ 271(a), (b), (c), and
`
`(g).
`
`32.
`
`Collegium without authority uses, offers to sell or sells in the United
`
`States the Collegium NDA products that use or, according to Collegium, contain the purified
`
`oxycodone base covered by claim 19 of the ’434 patent. Thus, Collegium is liable for infringement
`
`under 35 U.S.C. § 271(a).
`
`33.
`
`The marketing materials, and/or the labeling associated with the
`
`Collegium NDA Products, including, but not limited to, any package inserts, medication guides,
`
`full prescribing information, or other materials related to such labeling, instructs healthcare
`
`providers and patients to use the oxycodone base from the Collegium NDA Products made
`
`according to the process of one or more claims of the ’434 patent, thereby infringing the asserted
`
`
`
`- 7 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 8 of 15
`
`
`
`claims. Collegium intends to cause infringement of the ’434 patent and has knowledge that the
`
`use of the Collegium NDA Products according to Collegium’s instructions causes direct
`
`infringement of the ’434 patent under 35 U.S.C. § 271(g) by healthcare providers, physicians, other
`
`medical care workers, patients, and any other persons using the Collegium NDA Products. Thus,
`
`Collegium is liable for inducing infringement under 35 U.S.C. § 271(b) of those using the
`
`Collegium NDA Products.
`
`34.
`
`Collegium without authority uses, offers to sell or sells in the United
`
`States the Collegium NDA Products that use or, according to Collegium, contain the purified
`
`oxycodone base covered by claim 19 of the ’434 patent. Claim 19 recites “[p]urified oxycodone
`
`free base prepared according to the process of claim 2, wherein the ratio of 8α, 14-dihydroxy-7,8-
`
`dihydrocodeinone to oxycodone free base is 0.04% or less as measured by HPLC.” Based upon
`
`knowledge of Noramco’s oxycodone process and documents produced in the Lead Action,
`
`Noramco performs all the steps of claim 2 of the ’434 patent. Further, upon information and belief,
`
`the oxycodone base used in the Collegium NDA Products, and process intermediates of the
`
`oxycodone base of Noramco’s process, meets the 8α ratio claim element of claim 2 and the 8α
`
`ratio claim element of claim 19. Thus, Collegium is liable for infringement under 35 U.S.C. §
`
`271(a).
`
`35.
`
`Further, Collegium uses Patheon Pharmaceuticals Inc. (“Patheon”) as a
`
`contract manufacturer to make the Collegium NDA Products.
`
`36.
`
`Patheon makes the Collegium NDA Products using specifications and
`
`instructions from Collegium, including specification and manufacturing parameters set forth in
`
`Collegium’s NDA.
`
`
`
`- 8 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 9 of 15
`
`
`
`37.
`
`Patheon uses oxycodone base to make the Collegium NDA Products and
`
`makes the Collegium NDA Products in the United States.
`
`38.
`
`In making the Collegium NDA Products that will be used, offered for
`
`sale or sold under Collegium’s NDA, Patheon must follow the manufacturing parameters set forth
`
`in Collegium’s NDA. Thus, Patheon makes the Collegium NDA Products under Collegium’s
`
`direction and control.
`
`39.
`
`Accordingly, Collegium’s contract manufacturer, Patheon, under
`
`Collegium’s direction and control and pursuant to Collegium’s specifications and instructions,
`
`including specification and processes set forth in Collegium’s NDA, uses the purified oxycodone
`
`base covered by claim 19 of the ’434 patent to make the Collegium NDA Products. Thus,
`
`Collegium is directly liable for Patheon’s infringement of claim 19 of the ’434 patent under 35
`
`U.S.C. § 271(a).
`
`40.
`
`In addition, those manufacturing and/or using the oxycodone base used
`
`in the manufacture of the Collegium NDA Products pursuant to Collegium’s specifications,
`
`including Collegium’s NDA specifications and instructions, including but not limited to, for
`
`example, Noramco and/or Patheon, directly infringe one or more of at least claims 1-7, 9, 13-15,
`
`17 and 19 of the ’434 patent. Collegium intends to cause infringement of the ’434 patent and has
`
`knowledge that manufacturing of the oxycodone base used in the Collegium NDA Products and/or
`
`the Collegium NDA Products according to Collegium’s instructions and NDA specifications
`
`causes direct infringement of the ’434 patent by manufacturers. Thus, upon information and belief,
`
`Collegium is liable for inducing infringement under 35 U.S.C. § 271(b) of those manufacturing
`
`the oxycodone base used in the Collegium NDA Products and/or the Collegium NDA Products.
`
`
`
`- 9 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 10 of 15
`
`
`
`41.
`
`The oxycodone base used in the Collegium NDA Products constitutes a
`
`material part of the inventions covered by the claims of the ’434 patent, is especially made or
`
`adapted to infringe the asserted claims, and there are no substantial non-infringing uses for the
`
`oxycodone base used in Collegium NDA Products. Thus, Collegium is liable for contributory
`
`infringement under 35 U.S.C. § 271(c).
`
`42.
`
`Collegium without authority offers to sell, sells or uses within the United
`
`States the Collegium NDA Products that use, or according to Collegium, contain oxycodone base
`
`made by a process covered by at least claims 1-7, 9, 13-15 and 17 of the ’434 patent.
`
`43.
`
`Based upon knowledge of Noramco’s oxycodone process and documents
`
`produced in the Lead Action, Noramco performs all the steps of at least claims 1-7, 9, 13-15 and
`
`17 of the ’434 patent.
`
`44.
`
`Upon information and belief, the oxycodone base used in the Collegium
`
`NDA Products, and the process intermediates of the oxycodone base of Noramco’s process, meets
`
`the 8α ratio claim element contained in certain dependent claims.
`
`45.
`
`Further, the oxycodone base covered by the claims of the ’434 patent is
`
`not materially changed by subsequent processes, including formulation into the Collegium NDA
`
`Products and is not a trivial and nonessential component of the Collegium NDA Products. Thus,
`
`Collegium is directly liable for infringement under 35 U.S.C. § 271(g).
`
`46.
`
`Collegium without authority uses within the United States the oxycodone
`
`base made by a process covered by at least claims 1-7, 9, 13-15 and 17 of the ’434 patent.
`
`Specifically, Collegium’s contract manufacturer, Patheon, under Collegium’s direction and control
`
`and pursuant to Collegium’s specifications and instructions, including specification and processes
`
`
`
`- 10 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 11 of 15
`
`
`
`set forth in Collegium’s NDA, uses the oxycodone base covered by at least claims 1-7, 9, 13-15
`
`and 17 of the ’434 patent to make the Collegium NDA Products.
`
`47.
`
`Further, the oxycodone base covered by the claims of the ’434 patent is
`
`not materially changed by subsequent processes, including formulation into the Collegium NDA
`
`Products and is not a trivial and nonessential component of the Collegium NDA Products. Thus,
`
`Collegium is directly liable for Patheon’s direct infringement of at least claims 1-7, 9, 13-15 and
`
`17 of the ’434 patent under 35 U.S.C. § 271(g).
`
`COUNT II
`(Collegium’s Marketing of the Collegium NDA Products Infringes and Has Infringed the
`’434 Patent)
`
`48.
`
`Purdue incorporates by reference and realleges paragraphs 1-47 above as
`
`though fully restated herein.
`
`49.
`
`Upon information and belief, Collegium has begun commercial
`
`manufacture of the Collegium NDA Products, began offering for sale and selling the Collegium
`
`NDA Products, and continues to manufacture (or have manufactured), offer for sale, sell, and
`
`distribute the Collegium NDA Products.
`
`50.
`
`Since at least the issue date of the ’434 patent, Collegium has been
`
`infringing the ’434 patent by making, using, offering for sale, selling, and distributing products
`
`embodying the patented inventions in violation of 35 U.S.C. § 271(a) and (g), inducing others to
`
`make, use, sell, or offer for sale products and methods embodying the patented inventions in
`
`violation of 35 U.S.C. § 271(b), and/or by contributing to the manufacture, use, sale, or offer for
`
`sale of products embodying the patented inventions in violation of 35 U.S.C. § 271(c).
`
`51.
`
`Collegium’s infringement of the ’434 patent has been willful, egregious,
`
`and in disregard of the ’434 patent.
`
`
`
`- 11 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 12 of 15
`
`
`
`52.
`
`Collegium has had knowledge of the ’434 patent at or around the date of
`
`issuance of the ’434 patent, and no later than October 30, 2020.
`
`53.
`
`By the issue date of the ’434 patent or by at least October 30, 2020,
`
`Collegium has had knowledge that it had no good-faith non-infringement and invalidity positions
`
`regarding the ’434 patent.
`
`54.
`
`Purdue has been and will continue to be substantially and irreparably
`
`damaged and harmed by Collegium’s manufacture, use, sale, or offer for sale of the Collegium
`
`NDA Products if such infringement is not enjoined. Purdue does not have an adequate remedy at
`
`law.
`
`PRAYER FOR RELIEF
`
`WHEREFORE, Purdue prays for judgment:
`
`A.
`
`Adjudging that Collegium has infringed, and that Collegium’s commercial sale,
`
`offer for sale, use, manufacture, and/or importation of the Collegium NDA Products has infringed,
`
`induced infringement of, and/or contributed to the infringement of the ’434 patent;
`
`B.
`
`Adjudging, pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date of any approval
`
`of Collegium’s NDA, under § 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
`
`§ 355(b)(2)), to be a date not earlier than the date of expiration of the ’434 patent, plus any
`
`additional periods of exclusivity;
`
`C.
`
`Preliminarily and permanently enjoining, pursuant to 35 U.S.C. §§ 271(e)(4)(B)
`
`and 283 and Rule 65, Fed. R. Civ. P., Collegium, its officers, partners, agents, servants, employees,
`
`parents, subsidiaries, divisions, affiliate corporations, other related business entities, and all other
`
`persons acting in concert, participation, or in privity with them, and their successors and assigns,
`
`from any commercial manufacture, use, offer to sell, or sale within the United States, or
`
`importation into the United States, of any drug product that infringes the ’434 patent;
`
`
`
`- 12 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 13 of 15
`
`
`
`D.
`
`Awarding, pursuant to 35 U.S.C. §§ 271(e)(4)(C) and 284, damages to Purdue
`
`resulting from Collegium’s commercial manufacture, use, importation into the United States, offer
`
`for sale, or sale of the Collegium NDA Products prior to the expiration of the ’434 patent, increased
`
`to treble the amount found or assessed, together with interest;
`
`E.
`
`Declaring this an exceptional case and awarding Purdue its attorneys’ fees, as
`
`provided by 35 U.S.C. §§ 271(e)(4) and 285; and
`
`F.
`
`Awarding Purdue such other and further relief as this Court may deem just and
`
`proper.
`
`
`
`- 13 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 14 of 15
`
`
`
`Dated: April 9, 2021
`
`/s/ Christopher M. Morrison
`Christopher M. Morrison (BBO# 651335)
`JONES DAY
`100 High Street
`21st Floor
`Boston, MA 02110
`Telephone: (617) 960-3939
`Facsimile: (617) 449-6999
`cmorrison@jonesday.com
`
`John J. Normile (pro hac vice)
`JONES DAY
`250 Vesey Street
`New York, NY 10281-1047
`Telephone: (212) 326-3939
`Facsimile: (212) 755-7306
`jjnormile@jonesday.com
`
`Gregory Castanias (pro hac vice)
`Jennifer L. Swize (pro hac vice)
`JONES DAY
`51 Louisiana Avenue, N.W.
`Washington, D.C. 20001
`Telephone: (202) 879-3939
`Facsimile: (202) 626-1700
`gcastanias@jonesday.com
`jswize@jonesday.com
`
`Pablo D. Hendler (pro hac vice)
`POTOMAC LAW GROUP, PLLC
`1177 Avenue of the Americas, 5th Floor
`New York, NY 10036
`Telephone: (914( 893-6883
`Facsimile: (202) 318-7707
`phendler@potomaclaw.com
`
`Counsel for Plaintiffs
`
`
`
`
`
`
`- 14 -
`
`
`
`Case 1:21-cv-10598-FDS Document 1 Filed 04/09/21 Page 15 of 15
`
`
`
`CERTIFICATE OF SERVICE
`
`I, Christopher M. Morrison, hereby certify that I have on this 9 day of April 2021 filed a copy of
`the foregoing through the Court’s CM/ECF system, which will serve an electronic copy on
`counsel of record identified in the Notice of Electronic Filing.
`
`
`
`
`
`
`/s/ Christopher M. Morrison
`
`
`
`
`
`
`